13D·WATCH Activist + Insider Intelligence Live feed Blog About Pricing
SCHEDULE 13D/A Filed 2026-08-14 Event 2026-08-12 SEC 0000899140-26-000895 →

GMS Ventures & Investments → Outlook Therapeutics, Inc. OTLK

Stake: 16.40% Shares: 42,631,142 CUSIP: 69012T305 Class: Common Stock, par value $0.01 per share

Item 4 — Purpose of Transaction

Item 4 of the Schedule 13D is hereby amended to add the following after the last paragraph: On August 12, 2026, the Issuer entered into the sale of an aggregate of 55,555,556 Shares and accompanying Warrants to acquire up to an aggregate of 55,555,556 Shares in a registered underwritten public offering (the "August 2026 Offering"). GMS Ventures purchased 2,525,252 Shares and accompanying Warrants to purchase 2,525,252 Shares in the Offering, at a combined purchase price per Share and accompanying Warrant of $0.99, for an aggregate purchase price of approximately $2.5 million. Each Warrant will have an initial exercise price per share of $1.10, subject to certain customary adjustments for recapitalizations, stock splits and similar actions. The Warrants will be exercisable immediately and will expire five years from the date of issuance. The August 2026 Offering closed on August 14, 2026.

Cross-References

Insider Activity (last 365d)
9 transactions
7 buys · 0 sales · 0 awards/exercises
Issuer Cluster
16 13D/G filings on this issuer
15 other filings besides this one
Filer Track Record
3 filings by this filer
2 other filings in the data moat
Short Interest · settle 2026-09-30
DTC 7.11
31,896,591 shares short · -1.0% vs prior

Form 4 Insider Transactions · last 365d

DateInsiderRoleTypeSharesPriceValue
2026-08-14 KENYON LAWRENCE A director, officer Buy 101,010 — —
2026-08-14 KENYON LAWRENCE A director, officer Buy 101,010 $1.10 $111K
2026-08-12 Sukhtian Ghiath M. director, 10%+ owner Buy 2,525,252 $0.99 $2.50M
2026-08-12 Sukhtian Ghiath M. director, 10%+ owner Buy 2,525,252 $1.10 $2.78M
2026-05-28 Sukhtian Ghiath M. director, 10%+ owner Buy 8,539,709 $0.59 $5.00M
2026-05-28 Sukhtian Ghiath M. director, 10%+ owner H 3,458,571 $2.26 $7.82M
2026-05-28 Sukhtian Ghiath M. director, 10%+ owner Buy 3,458,571 $0.59 $2.02M
2026-05-28 Sukhtian Ghiath M. director, 10%+ owner H 8,571,428 $1.40 $12.00M
2026-05-28 Sukhtian Ghiath M. director, 10%+ owner Buy 8,571,428 $0.59 $5.02M

Other 13D/G Filings on Outlook Therapeutics, Inc.

FiledFormFilerStakeShares
2026-08-19 SCHEDULE 13G CVI Investments, Inc. — — view →
2026-06-01 SCHEDULE 13D/A GMS Ventures & Investments — 37,580,638 view →
2025-01-22 SCHEDULE GMS Ventures & Investments 38.60% 12,725,216 view →
2022-07-08 SC Tenshi Healthcare Pte. Ltd. — — view →
2022-02-01 SC BioLexis Pte Ltd. — — view →
2021-02-05 SC Syntone Ventures LLC — — view →
2021-02-02 SC BioLexis Pte Ltd. — — view →
2020-03-24 SC BioLexis Pte Ltd. — — view →
2020-02-27 SC BioLexis Pte Ltd. — — view →
2020-01-31 SC BioLexis Pte Ltd. — — view →
2019-12-30 SC BioLexis Pte Ltd. — — view →
2019-04-17 SC BioLexis Pte Ltd. — — view →
2019-02-05 SC BioLexis Pte Ltd. — — view →
2019-01-03 SC BioLexis Pte Ltd. — — view →
2018-01-05 SC SABBY MANAGEMENT, LLC — — view →

Other Filings by GMS Ventures & Investments

FiledFormIssuerStakeShares
2026-06-01 SCHEDULE 13D/A Outlook Therapeutics, Inc. OTLK — 37,580,638 view →
2025-01-22 SCHEDULE Outlook Therapeutics, Inc. OTLK 38.60% 12,725,216 view →

Want this depth on every filing the moment it hits SEC EDGAR?

Full feed access · API · daily intelligence brief · custom alerts. From $49/mo.

See pricing →